Scarica l'app Stockscreener
10.94
4.54%
-0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.46
Aprire:
$11.47
Volume 24 ore:
363.46K
Relative Volume:
1.11
Capitalizzazione di mercato:
$181.40M
Reddito:
$99.61M
Utile/perdita netta:
$-153.60M
Rapporto P/E:
-0.6651
EPS:
-16.4479
Flusso di cassa netto:
$-152.14M
1 W Prestazione:
-23.34%
1M Prestazione:
-29.87%
6M Prestazione:
-62.73%
1 anno Prestazione:
+24.22%
Intervallo 1D:
$10.59
$11.47
Intervallo di 1 settimana:
$10.36
$14.21
Portata 52W:
$7.15
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
10.94 | 181.40M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-30 | Ripresa | Wells Fargo | Overweight |
| 2026-08-07 | Iniziato | Stifel | Buy |
| 2026-06-11 | Ripresa | Truist | Buy |
| 2026-05-28 | Iniziato | Barclays | Overweight |
| 2026-05-15 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2026-04-30 | Iniziato | Mizuho | Outperform |
| 2026-04-07 | Iniziato | Leerink Partners | Outperform |
| 2026-03-24 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-05-08 | Iniziato | BofA Securities | Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-06 | Iniziato | Oppenheimer | Outperform |
| 2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2021-06-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-07-16 | Iniziato | Wells Fargo | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-10-07 | Iniziato | BTIG Research | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference - Yahoo! Finance Canada
Sutro Biopharma (STRO) Pulls Back 6.85% to $14.27 as Shares Test Key Support ZoneVolume Nodes - https://www.siam.in/
Sutro Biopharma Inc (STRO-Q) Stock Price and News - The Globe and Mail
Sutro Biopharma appoints Lucas Donigian as business head - Investing.com
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development - Yahoo Finance
An oncology dealmaker with partnerships worth over $2 billion joins Sutro - Stock Titan
Form 4 Sutro Biopharma For: 27 September - Investing.com India
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to S&P Global BMI Index - marketscreener.com
Sutro Biopharma Stock Price Forecast. Should You Buy STRO? - StockInvest.us
Sutro Biopharma (STRO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
A Quick Look at Today's Ratings for Sutro Biopharma(STRO.US), With a Forecast Between $49 to $56 - Moomoo
Mackay Gold & Silver: Mackay Gold & Silver Adds Second Drill Rig to Test the Historic Sutro Tunnel Intersection of the Occidental-Brunswick Lode at Depth, Comstock District, Nevada - FinanzNachrichten.de
Merck & Co. Inc. Invests $9.04 Billion in Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma (STRO) Climbs 2.91% as Shares Test Key Resistance at $22.12New Highs New Lows - vinanet.vn
Stifel Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Sutro Biopharma (STRO) Shares Slide 3.89% to $20.48 as Selling Pressure IntensifiesDealer Positioning - vinanet.vn
Broker Revenue Forecasts For Sutro Biopharma, Inc. (NASDAQ:STRO) Are Surging Higher - simplywall.st
Earnings Beat: Sutro Biopharma, Inc. (NASDAQ:STRO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Moomoo
Sutro Biopharma (NasdaqGM:STRO) Stock Forecast & Analyst Predictions - Simply Wall Street
Sutro Biopharma, Inc. (NASDAQ:STRO) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Sutro Biopharma (STRO): Perceptive Advisors reports 7.9% beneficial stake - Stock Titan
Sutro Biopharma (STRO): Point72 group reports 1.4% stake in 13G/A - Stock Titan
Sutro Biopharma Q3 EPS Forecast Reduced by HC Wainwright - MarketBeat
BofA Securities Maintains Sutro Biopharma(STRO.US) With Sell Rating - Moomoo
STRO Maintained by Citizens -- Price Target Lowered to $34.00 - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $34.00 at Citizens Jmp - MarketBeat
STRO Reiterated by Wedbush -- Price Target Maintained at $60 - GuruFocus
Truist Financial Maintains Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (NASDAQ:STRO) Earns Outperform Rating from Wedbush - MarketBeat
Citizens cuts Sutro Biopharma stock price target on revenue miss - Investing.com
Citizens cuts Sutro Biopharma stock price target on revenue miss By Investing.com - Investing.com Canada
Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Is Sutro Biopharma Inc (STRO) Facing Pressures After Q2 Earnings - GuruFocus
Sutro Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Why is Sutro Biopharma Stock Falling On Wednesday? - TradingView
Sutro Biopharma (NASDAQ:STRO) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Sutro Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sutro Biopharma Reports Q2 2026 Financial Results and Pipeline Update - Kalkine Media
Sutro Biopharma Announces Q2 2026 Financial Results and Updates Corporate Presentation - Kalkine Media
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com Nigeria
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com South Africa
Sutro Biopharma Q2 Results Highlight Advancing ADC Pipeline - TipRanks
Sutro reports early clinical responses from STRO-004 cancer trial By Investing.com - Investing.com Australia
SUTRO BIOPHARMA, INC. 2Q 2026: Revenue $9.84M, EPS ($2.33) — 10-Q Summary - TradingView
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com Canada
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com India
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com Australia
Sutro Biopharma (STRO) revenue drops as cash rises after $110M stock sale - Stock Titan
Form 8K Sutro Biopharma For: 12 August By Investing.com - Investing.com UK
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sutro Biopharma Inc Azioni (STRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Chow Gregory K. | CFO |
Jun 02 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
4,725 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| BARBARA LEYMAN | Former Officer |
Jan 20 '26 |
Proposed Sale |
14.67 |
8,929 |
130,962 |
0 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):